BioTime Announces $1.9 Million Grant for Continued Development of OpRegen® for Dry-AMD
BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, has been awarded a new grant for 2018 of up to 6.9 million Israeli New Shekels (approximately $1.9 million) from the Israel Innovation Authority (the “IIA”). The grant provides funding for the continued development of OpRegen®, and to date the IIA has provided annual grants totaling over $13 million.
OpRegen® is currently in a Phase I/IIa clinical study, which in March 2018 received authorization from the Data Safety Monitoring Board (DSMB) to move forward with enrollment of cohort 4. The DSMB approval was based on the safety observed throughout the first three cohorts. Safety will remain the primary focus of cohort 4. The fourth cohort will include better vision patients than the previous three cohorts. These better vision patients will likely be in earlier stages of the disease and allow for a wide range of preliminary functional assessment measurements. These earlier stage patients will likely be the target patient population for this therapy and BioTime expects to share initial data from cohort 4 in the coming months.
“The IIA’s continued support is encouraging and shows their commitment and confidence in our ability to continue the development of OpRegen, our lead cell replacement program,” said Adi Mohanty, co-Chief Executive Officer of BioTime.
About OpRegen ®
OpRegen®, which is being studied for the treatment of the dry form of AMD, consists of a suspension of retinal pigment epithelial (RPE) cells that are delivered subretinally during a simple intraocular injection. RPE cells are essential components of the back lining of the retina, and function to help nourish the retina including photoreceptors. A proprietary process that drives the differentiation of human pluripotent stem cells is used to generate high purity OpRegen® RPE cells. OpRegen® RPE cells are also “xeno-free,” meaning that no animal products are used at any point in the derivation and production process. The avoidance of the use of animal products eliminates some potential safety concerns. Preclinical studies in rats have shown that following a single subretinal injection of OpRegen®, the cells can rapidly organize into its natural monolayer structure in the subretinal space and survive throughout the lifetime of the animal. OpRegen® is designed to be an “off-the-shelf” allogeneic (non-patient specific) product. Unlike treatments that require multiple, frequent injections into the eye, it is expected that OpRegen® will be administered in a single procedure. OpRegen® was granted Fast Track designation from the FDA, which allows more frequent interactions with the agency, and eligibility for accelerated approval and priority review. OpRegen® is a registered trademark of Cell Cure Neurosciences Ltd., a majority-owned subsidiary of BioTime, Inc.
About BioTime, Inc.
BioTime is a clinical-stage biotechnology company focused on degenerative diseases. Its clinical programs are based on two platform technologies: cell replacement and cell/drug delivery. With its cell replacement platform, BioTime is producing new cells and tissues with its proprietary pluripotent cell technologies. These cells and tissues are developed to replace those that are either rendered dysfunctional or lost due to degenerative diseases or injuries. BioTime’s cell/drug delivery programs are based upon its proprietary HyStem® cell and drug delivery matrix technology. HyStem® was designed, in part, to provide for the transfer, retention and/or engraftment of cellular replacement therapies. BioTime’s lead cell delivery clinical program is Renevia®, which consists of HyStem® combined with the patient's own adipose (fat) progenitor cells. Renevia® met its primary endpoint in an EU pivotal clinical trial for the treatment of facial lipoatrophy in HIV patients in 2017. BioTime has submitted Renevia® for CE Mark approval in the EU. There were no device related serious adverse events reported to date. BioTime’s lead cell replacement product candidate is OpRegen®, a retinal pigment epithelium transplant therapy, which is in a Phase I/IIa multicenter clinical trial for the treatment of dry age-related macular degeneration, the leading cause of blindness in developing countries. There were no unexpected serious adverse events reported to date. BioTime also has significant equity holdings in two publicly traded companies, Asterias Biotherapeutics, Inc. (NYSE American: AST) and OncoCyte Corporation (NYSE American: OCX), and a private company, AgeX Therapeutics, Inc.
BioTime common stock is traded on the NYSE American and TASE under the symbol BTX. For more information, please visit www.biotime.com or connect with the company on Twitter, LinkedIn, Facebook, YouTube, and Google+.
To receive ongoing BioTime corporate communications, please click on the following link to join the Company’s email alert list: http://news.biotime.com.
Certain statements contained in this release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Statements pertaining to product technology, clinical development, regulatory approval timelines, the success of potential cosmetic applications and potential opportunities for BioTime, Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates” should also be considered forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty as to the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of BioTime, Inc. and its subsidiaries, particularly those mentioned in the cautionary statements found in more detail in the “Risk Factors” section of BioTime’s Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q filed with the SEC (copies of which may be obtained at www.sec.gov). Subsequent events and developments may cause these forward-looking statements to change. BioTime specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law.
David Nakasone, 510-871-4188
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Citi Private Bank Issues Mid-Year Outlook 2020, Investing in a New Economic Cycle4.6.2020 21:07:00 CEST | Press release
Citi Private Bank today released its Mid-Year Outlook 2020 report, Investing in a New Economic Cycle. Released twice yearly, this edition calls for major changes to client portfolios as a new economic and market cycle begins. Citi Private Bank expects a more rapid economic rebound than many others. However, the report stresses that this is no ordinary recovery; just as the COVID collapse is no ordinary recession. Large disparities in various countries’ economic growth seem likely owing to significant differences in national stimulus efforts. Greater exposure to trade and tourism is also likely to see certain countries bounce back more slowly. “The global investment landscape has changed dramatically as a result of the pandemic,” said David Bailin, Chief Investment Officer, Citi Private Bank. “We expect massive dispersion in potential returns between regions, industries, and countries as the world transitions from fear to prosperity. The impact of unprecedented stimulus measures upon va
Monument Re Completes Acquisition of Cattolica Life DAC4.6.2020 19:59:00 CEST | Press release
Monument Re announced today that it has completed the acquisition of Cattolica Life DAC from Cattolica Assicurazioni following receipt of regulatory approval from the Central Bank of Ireland and no-objection from the Bermuda Monetary Authority. About Cattolica Assicurazioni. Cattolica Assicurazioni is one of the main players on the Italian insurance market and the only cooperative company in its industry to be listed on the Milan Stock Exchange, where it has been present since November 2000. With nearly 3.6 million customers who rely on the insurance solutions and products it distributes, the Group has total premiums of nearly €6 billion (2018). About Monument Re Monument Re Limited is a life Reinsurance and Insurance Holding Company with a presence in Bermuda, Ireland, Belgium, Luxembourg, the Netherlands and Guernsey, with branches in Spain, Italy, France and Germany. Monument Re operates as a reinsurer and acquirer of European asset intensive portfolios. Through this strategy, Monum
To Help Building and Facilities Managers Meet the Demands of Social Distancing, Bentley Systems Opens Up Full Access to LEGION Simulator and OpenBuildings Station Designer and Waives Subscription Fees through September 304.6.2020 18:03:00 CEST | Press release
Bentley Systems, Incorporated, a leading global provider of comprehensive software and digital twins services for advancing the design, construction, and operations of infrastructure, today announced it has opened up its LEGIONSimulator and OpenBuildings Station Designer software, including waiving new subscription fees through September 30, 2020, for facilities managers to incorporate pedestrian simulation methodologies across their planning, design, and operations teams. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200604005622/en/ Top left illustrates a 3D model of a retail operation created using OpenBuildings Station Designer. Bottom left shows 2D floor plans that are then imported into LEGION Simulator (right) to test two scenarios. Examples shown are at occupancy rates of 75% (top) and 25% (bottom) to comply with social distancing requirements. (Photo: Business Wire) With social distancing and crowd management at th
European Commission Grants Marketing Authorisation for DARZALEX ® ▼ (daratumumab) Subcutaneous Formulation for all Currently Approved Daratumumab Intravenous Formulation Indications4.6.2020 16:00:00 CEST | Press release
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the European Commission (EC) has granted marketing authorisation for DARZALEX®▼(daratumumab) subcutaneous (SC) formulation for the treatment of adult patients with multiple myeloma (MM). Daratumumab SC is administered as a fixed dose, which significantly reduces treatment time, from hours to approximately three to five minutes, when compared to daratumumab intravenous (IV) formulation.1 In addition, only the first dose of daratumumab SC needs to be administered in an environment where resuscitation facilities are available. The approval applies to all current daratumumab indications in frontline and relapsed/refractory settings, and patients currently on daratumumab IV can switch to the SC formulation should they choose to. Data supporting the approval show that daratumumab SC demonstrated a consistent overall response rate (ORR) and a similar safety profile compared with daratumumab IV in patients with rela
HCL and Google Cloud Expand Partnership to Digitally Transform Commerce4.6.2020 16:00:00 CEST | Press release
HCL Technologies (HCL), a leading global technology company, and Google Cloud today announced the expansion of their strategic partnership to bring HCL's software offerings, starting with HCL Commerce, to Google Cloud. Google Cloud will be the preferred cloud platform for HCL Commerce, providing global, secure and elastic infrastructure to power businesses’ eCommerce strategies. Under this partnership, HCL also intends to leverage Anthos to enable multi-cloud and hybrid-cloud deployments of HCL Commerce. HCL Commerce is a leading, cloud-native Commerce platform used by innovative businesses across multiple industries and around the world to drive more than $100 billion in annual client revenues. With a strong track-record of delivering rock-solid performance, scalability and functionality, HCL Commerce today is at the forefront of many organizations’ digital commerce strategies. It stretches far beyond an initial transaction and enables businesses to respond to evolving market conditio
AT&T ® México Selects MATRIXX Software for Prepaid Platform Replacement4.6.2020 15:00:00 CEST | Press release
MATRIXX Software today announced that https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.att.com.mx&esheet=52230127&newsitemid=20200604005138&lan=en-US&anchor=AT%26amp%3BT%26%23174%3B+M%26eacute%3Bxico&index=2&md5=52456f1fe4eebcb68026fb5ad3b2dd58 AT&T® México, a subsidiary of AT&T® USA and one of the largest mobile players in the Mexican market, is deploying MATRIXX Software’s cloud native digital commerce platform for its prepaid customers. MATRIXX Digital Commerce is replacing multiple legacy Intelligent Network (IN) and Business Support Systems (BSS) to provide a future-proof, web-scale BSS that will allow for greater innovation and business agility. MATRIXX will support both the AT&T brand and UNEFON brand on a single platform. The industry’s leading solution for real-time cloud native rating and convergent charging for 5G(CCS) and 4G(OCS), MATRIXX Digital Commerce was selected after a rigorous evaluation process that included multiple vendors. “We are proud to be